Navigation Links
Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
Date:10/20/2010

rference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a library of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration.  Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The company's strong and diverse intellectual property portfolio includes exclusive licenses from the University of Massachusetts Medical School on three patent families associated with the "Zamore Design Rules," which cover broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is headquartered in London, UK, with research and development activities in Berlin and operations in Redwood City, CA.

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.


'/>"/>
SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
2. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
3. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
4. Silence Therapeutics Appoints New Vice President of Research
5. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
6. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
7. Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
8. Fate Therapeutics Announces Collaboration With BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology
9. Northwest Biotherapeutics to Present at Inaugural Cancer Immunotherapy Conference
10. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
11. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... FRANCISCO, Calif. , May 5, 2015 ... treatment of cancer, today announced that Sean McCarthy ... the Credit Suisse Antibody Day in New ... May 6. Dr. McCarthy will present an overview of ... and Probody drug conjugate programs. About CytomX ...
(Date:5/5/2015)... , May 5, 2015   Tocagen ... that David R. Parkinson , M.D., a ... been appointed to the board of directors of ... of experience in oncology clinical development, including leading ... in global approvals of the cancer therapeutics Gleevec®, ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 GEA ... last week as recipients of the INTERPHEX Exhibitor ... recognition of their Portable, Continuous, Miniature and Modular ... a small footprint, continuous processing equipment, smart control ... process API powders and inactive ingredients into bulk ...
(Date:5/5/2015)... CA (PRWEB) May 05, 2015 Synedgen ... Nguyen, PhD as Regulatory Affairs Manager. , Dr. Nguyen ... an important juncture for the company as it moves ... drug products over the next two years. Dr. Nguyen ... of all the regulatory key documents that must be ...
Breaking Biology Technology:Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3Synedgen Announces the Appointment of Regulatory Affairs Manager 2
... , , ... , , , ... (DPD), and thymidylate,synthase (TS) play a pivotal role in the ... (5-FU) is the standard,chemotherapy treatment for a wide range of ...
... , , , ... , RNA interference is a powerful technique for gene,knockdown experiments ... research. , , , ... cell lines are used for,gene knockdown experiments, and in many cases protocols,for transfection ...
... , ... , , , ... against invasion of foreign genes,appeared a few years ago, RNAi has ... mediated by short double-stranded RNAs that are,homologous to the suppressed gene. ...
Cached Biology Technology:Gene-Expression Analysis of TP, DPD, and TS Using,the LightCycler mRNA Quantification KitsPLUS 2Gene-Expression Analysis of TP, DPD, and TS Using,the LightCycler mRNA Quantification KitsPLUS 3Gene-Expression Analysis of TP, DPD, and TS Using,the LightCycler mRNA Quantification KitsPLUS 4Housekeeping Genes: Universal Positive,Controls in siRNA Knockdown Experiments 2Housekeeping Genes: Universal Positive,Controls in siRNA Knockdown Experiments 3Quantification of siRNA Silencing Efficiency,Using the LightCycler System 2Quantification of siRNA Silencing Efficiency,Using the LightCycler System 3Quantification of siRNA Silencing Efficiency,Using the LightCycler System 4Quantification of siRNA Silencing Efficiency,Using the LightCycler System 5
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/9/2015)... SAN JOSE, Calif. , April 9, 2015 /PRNewswire/ ... of human interface solutions, announced today that it will ... 2015 on Thursday, April 23, 2015, after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... Sequencing Center at Washington University School of Medicine increased ... additional Genome Sequencer FLX Systems from Roche Diagnostics. ... the Genome Sequencing Center will be able to support ... technology, ranging from the sequencing of new complex genomes ...
... of new genome sequencing technology has prompted a ... hypothesis about how agricultures early beginnings may have ... Vinatzer, assistant professor of plant pathology, physiology, and ... Life Sciences, has received a $1 million, five-year ...
... the New York-based Doris Duke Charitable Foundation (DDCF), Carnegie ... of investigators from Carnegie Mellon, the University of Minnesota, ... law firm Van Ness Feldman to develop and promote ... transport and deep geological sequestration of carbon dioxide (CO ...
Cached Biology News:Washington University increases fleet of Roche Genome Sequencer FLX Systems 2Washington University increases fleet of Roche Genome Sequencer FLX Systems 3Tomato pathogen genome may offer clues about bacterial evolution at dawn of agriculture 2Carnegie Mellon receives $1.85 million 2
Synonym: modified Grace's Insect medium...
... acid synthetic peptide whose sequence is derived from bovine rhodopsin ... carboxy terminus): C - S(338) - K - T ... - A - P - A(348). This peptide ... polyclonal antibody that reacts with this product and bovine rhodopsin, ...
... The proteomic service includes protein separation ... using the PDQuest software package from ... mass spectrometry. In order to meet ... preparation, data analysis and format of ...
b6-2A12...
Biology Products: